{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:04:04Z","timestamp":1786122244651,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin\u2010based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical development.<\/jats:p>\n                    <jats:p>To describe a methodological framework for a series of systematic reviews and network meta\u2010analyses aimed at comparing approved and investigational obesity management medications (OMMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This article presents the methodological framework for a series of systematic reviews and network meta\u2010analyses that will be conducted according to PRISMA 2020, PRISMA\u2010NMA and PRISMA\u2010P recommendations. Separate reviews and network meta\u2010analyses will be performed for individual pharmacological classes of OMMs. Treatment nodes will be defined as molecule\u2010dose combinations, selecting the highest approved dose for marketed therapies and the highest tested dose for investigational agents. Eligible studies will include randomised Phase 1\u20134 trials conducted in adults with overweight or obesity, with or without Type 2 diabetes. The primary outcome will be percentage total body weight loss at approximately 24\u201326\u2009weeks. Risk of bias and certainty of evidence will be assessed using RoB 2 and CINeMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The framework identifies 40 obesity investigational molecules that have completed at least Phase 1 development and groups them into 13 major mechanistic classes and nine approved therapies for the treatment of obesity. The present framework, therefore, encompasses 49 molecules which will serve as candidate interventions for future class\u2010specific network meta\u2010analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This paper presents a dose\u2010informed methodological framework for future evidence syntheses in obesity pharmacotherapy, supporting comparative evaluation and contextual positioning of next\u2010generation OMMs.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trail Registration:<\/jats:bold>\n                      PROSPERO\u2014CRD420261425340.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71046","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:01:28Z","timestamp":1782964888000},"page":"7768-7778","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positioning Incretin\u2010Based and Next\u2010Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta\u2010Analyses"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-828X","authenticated-orcid":false,"given":"Matteo","family":"Monami","sequence":"first","affiliation":[{"name":"Careggi Teaching Hospital and University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Ragghianti","sequence":"additional","affiliation":[{"name":"Careggi Teaching Hospital and University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-9408","authenticated-orcid":false,"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Careggi Teaching Hospital and University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03765-w"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03978-z"},{"issue":"4","key":"e_1_2_11_4_1","first-page":"1452","article-title":"Efficacy and Safety of European Medicines Agency (EMA)\u2010Approved Pharmacological, Endoscopic, and Surgical Treatments in Different Classes of Obesity: A Network Meta\u2010Analysis of Randomised Controlled Trials for the Development of the SIO Italian Guidelines for the Diagnosis and Treatment of Overweight and Obesity","volume":"27","author":"Barazzoni R.","year":"2025","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00656-2"},{"key":"e_1_2_11_6_1","volume-title":"Foundayo (Orforglipron) Prescribing Information","author":"US Food and Drug Administration","year":"2026"},{"key":"e_1_2_11_7_1","first-page":"1443","article-title":"Oral Semaglutide at a Dose of 25 mg in Adults With Overweight or Obesity","volume":"392","author":"Wharton S.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_10_1","first-page":"1021","article-title":"Tirzepatide Versus Semaglutide Once Weekly in Patients With Obesity: The SURMOUNT\u20105 Trial","volume":"393","author":"Aronne L. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"e_1_2_11_11_1","first-page":"367","article-title":"Current and Future Medications for Obesity Treatment","volume":"334","author":"Kushner R. F.","year":"2025","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"e_1_2_11_12_1","first-page":"645","article-title":"New Molecules and Indications for GLP\u20101 Medicines","volume":"334","author":"Gonzalez\u2010Rellan M. J.","year":"2025","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"e_1_2_11_13_1","first-page":"512","article-title":"Efficacy and Safety of GLP\u20101 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian Network Meta\u2010Analysis","volume":"33","author":"Sinha B.","year":"2025","journal-title":"Obesity"},{"issue":"1","key":"e_1_2_11_14_1","first-page":"102","article-title":"Efficacy, Safety and PK of Once\u2010Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model\u2010Informed Drug Development Approach","volume":"28","author":"Overgaard R. V.","year":"2026","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"e_1_2_11_15_1","first-page":"1801","article-title":"Coadministered Cagrilintide and Semaglutide in Adults With Overweight or Obesity","volume":"392","author":"Garvey W. T.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_11_16_1","first-page":"377","article-title":"Once\u2010Weekly Semaglutide 7.2 mg in Adults With Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial","volume":"13","author":"Wharton S.","year":"2025","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"key":"e_1_2_11_18_1","first-page":"1557","article-title":"Orforglipron, an Oral Small\u2010Molecule GLP\u20101 Receptor Agonist for Obesity Treatment","volume":"392","author":"Wharton S.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"e_1_2_11_19_1","first-page":"601","article-title":"Once\u2010Weekly Semaglutide 7.2 mg in Adults With Obesity and Type 2 Diabetes (STEP UP T2D): A Randomised, Controlled, Phase 3b Trial","volume":"13","author":"Lingvay I.","year":"2025","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"e_1_2_11_20_1","first-page":"111560","article-title":"Updating the PRISMA Reporting Guideline for Network Meta\u2010Analysis: A Scoping Review","volume":"179","author":"Veroniki A. A.","year":"2025","journal-title":"Journal of Clinical Epidemiology"},{"key":"e_1_2_11_21_1","first-page":"111732","article-title":"Gaps in Completeness of Reporting and Methodological Quality: A Metaresearch Study of 139 Network Meta\u2010Analyses Published in January 2023 Using PRISMA\u2010NMA and AMSTAR\u20102","volume":"180","author":"Gianola S.","year":"2025","journal-title":"Journal of Clinical Epidemiology"},{"key":"e_1_2_11_22_1","unstructured":"\u201cPharmacological Treatments for Adults With Overweight and Obesity Without Diabetes \u201dhttps:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD015861\/full. Accessed Apr 27th 2026."},{"key":"e_1_2_11_23_1","unstructured":"\u201cEfficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta\u2010Analysis \u201dhttps:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023473597. Accessed Apr 27th 2026."},{"key":"e_1_2_11_24_1","unstructured":"\u201cMultimodal Clinical Algorithms With GLP\u20101 RA or GLP\u20101\/GIP Dual Agonists for the Management of Obesity in Adults: Protocol for a Component\u2010Network Meta\u2010Analysis \u201dhttps:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250653663. Accessed Apr 27th 2026."},{"key":"e_1_2_11_25_1","unstructured":"\u201cSystematic Review and Network Meta\u2010Analysis of Efficacy of Tirzepatide Semaglutide Liraglutide Bupropion\/Naltrexone and Phentermine\/Topirimate Pharmacotherapy for Weight Loss and Narrative Synthesis of Behavioural Mechanisms of Action \u201dhttps:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024613024. Accessed Apr 27th 2026."},{"key":"e_1_2_11_26_1","unstructured":"\u201cThe Effectiveness and Safety of Anti\u2010Obesity Drugs Currently Used in the UK for Weight Loss: Living Network Meta\u2010Analysis \u201dhttps:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024597606. Accessed Apr 27th 2026."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2864"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"e_1_2_11_29_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated August 2023)","author":"Higgins J. P.","year":"2023"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"issue":"11","key":"e_1_2_11_31_1","first-page":"1845","article-title":"Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial","volume":"12","author":"Kosiborod M. N.","year":"2024","journal-title":"JACC Heart Failure"},{"key":"e_1_2_11_32_1","first-page":"1934","article-title":"Cagrilintide\u2010Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes","volume":"392","author":"Davies M. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_11_33_1","first-page":"233","article-title":"Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction\u2010Associated Steatotic Liver Disease in People With Obesity: A Systematic Review and Network Meta\u2010Analysis of Randomised Controlled Trials","volume":"28","author":"Monami M.","year":"2026","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23902"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.3599"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250502"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-025-01747-y"},{"issue":"1","key":"e_1_2_11_40_1","article-title":"Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity","volume":"13","author":"American Diabetes Association Professional Practice Committee for Obesity","year":"2026","journal-title":"BMJ Open Diabetes Research & Care"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:51:52Z","timestamp":1786092712000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.71046"],"URL":"https:\/\/doi.org\/10.1111\/dom.71046","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.71046\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71046\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}